Results by group307

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 307

Download this page as JSON

Outcome	Group	Category	Value	Spread	Units
Baseline Exercise Capacity as Measured by the 6-Minute Walk Distance Test	Ambrisentan 2.5 mg		350.3	Standard Deviation 86.64	Meters
Baseline Exercise Capacity as Measured by the 6-Minute Walk Distance Test	Ambrisentan 5 mg		347.7	Standard Deviation 87.33	Meters
Baseline Exercise Capacity as Measured by the 6-Minute Walk Distance Test	Ambrisentan 10 mg		342.3	Standard Deviation 80.84	Meters
Baseline Exercise Capacity as Measured by the 6-Minute Walk Distance Test	Combined Ambrisentan Group		347.0	Standard Deviation 85.39	Meters
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 2.5 mg	Headache - Mild	1		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 5 mg	Headache - Mild	20		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 10 mg	Headache - Mild	36		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 2.5 mg	Headache - Moderate	0		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 5 mg	Headache - Moderate	14		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 10 mg	Headache - Moderate	17		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 2.5 mg	Headache - Severe	0		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 5 mg	Headache - Severe	0		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 10 mg	Headache - Severe	8		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 2.5 mg	Pulmonary hypertension (worsening) - Mild	2		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 5 mg	Pulmonary hypertension (worsening) - Mild	2		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 10 mg	Pulmonary hypertension (worsening) - Mild	7		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 2.5 mg	Pulmonary hypertension (worsening) - Moderate	4		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 5 mg	Pulmonary hypertension (worsening) - Moderate	10		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 10 mg	Pulmonary hypertension (worsening) - Moderate	29		participants
Frequently Reported (15% or More Overall) Adverse Events by Severity	Ambrisentan 2.5 mg	Pulmonary hypertension (worsening) - Severe	6		participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00578786/results

API reference For AI assistants

Results by group307

Sources 3

Read this list from software.